Loading...
Market
What percentage of commercial patients will have coverage for Rezdiffra by end of Q4 2024?
2
Resolution / Starting Odds
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Madrigal Pharmaceuticals' Q4 2024 financial report or official statements
Story
Madrigal's Rezdiffra Launches Strongly with $14.6M Sales
Aug 7, 2024, 08:04 PM
Madrigal Pharmaceuticals has reported a successful launch of its new drug, Rezdiffra, which is the first approved treatment for MASH (Metabolic Associated Steatohepatitis). In the second quarter of 2024, Rezdiffra achieved net sales of $14.6 million, exceeding expectations. The company has secured coverage for more than 50% of commercial patients, with less than 5% requiring a liver biopsy. The launch is expected to gain momentum, with plans to reduce the time to fill prescriptions from 60 days to 30 days by the end of the next quarter. Additionally, Madrigal is preparing for potential EMA approval in 2025.
View original story
Similar markets
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20 • 33%
20-40 • 33%
More than 40 • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
All major insurers • 25%
Most major insurers • 25%
Some major insurers • 25%
Few or none • 25%